Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Clinical trial NCT03698994 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03698994
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Malignant Solid Neoplasm Recurrent Ependymal Tumor Recurrent Ewing Sarcoma Recurrent Glioma Recurrent Hepatoblastoma Recurrent Histiocytic and Dendritic Cell Neoplasm Recurrent Langerhans Cell Histiocytosis Recurrent Malignant Germ Cell Tumor Recurrent Malignant Solid Neoplasm Recurrent Medulloblastoma Recurrent Neuroblastoma Recurrent Non-Hodgkin Lymphoma

Start date: 2018-11-14
Primary completion: 2022-03-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.